APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Viral Gene Therapy Market Analysis and Forecast 2026-2032

Report ID 174046480219 December 2025197 pages

Choose your research edition.

Industry ResearchViral Gene Therapy Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Gene Therapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Viral Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Gene Therapy Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Gene Therapy Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Viral Gene Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Viral Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Viral Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Viral Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Viral Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Viral Gene Therapy include AnGes, Catalent, Ionis Pharmaceuticals, Orchard Therapeutics, Sarepta Therapeutics, SIBIONO, Spark Therapeutics, Amgen and Biogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Viral Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Viral Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Viral Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Viral Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Viral Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Viral Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Viral Gene Therapy Segment by Company

AnGes

Catalent

Ionis Pharmaceuticals

Orchard Therapeutics

Sarepta Therapeutics

SIBIONO

Spark Therapeutics

Amgen

Biogen

Gilead Sciences

Lonza

Novartis

Shanghai Sunway Biotech

Viral Gene Therapy Segment by Type

Integrating Viral Vectors

Non-Integrating Viral Vectors

Viral Gene Therapy Segment by Application

Ophthalmologic Diseases

Hematologic Diseases

Cardiovascular Diseases

Muscular Diseases

Metabolic Diseases

Infectious Diseases

Others

Viral Gene Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Viral Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Viral Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Gene Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Viral Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Integrating Viral Vectors Major Player Table 3. Non-Integrating Viral Vectors Major Player Table 4. Global Viral Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Ophthalmologic Diseases Major Player Table 6. Hematologic Diseases Major Player Table 7. Cardiovascular Diseases Major Player Table 8. Muscular Diseases Major Player Table 9. Metabolic Diseases Major Player Table 10. Infectious Diseases Major Player Table 11. Others Major Player Table 12. Viral Gene Therapy Industry Trends Table 13. Viral Gene Therapy Industry Drivers Table 14. Viral Gene Therapy Industry Opportunities and Challenges Table 15. Viral Gene Therapy Industry Restraints Table 16. Global Viral Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Viral Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Viral Gene Therapy Market Share by Region (2021-2026) Table 19. Global Viral Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Viral Gene Therapy Market Share by Region (2027-2032) Table 21. Global Viral Gene Therapy Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Viral Gene Therapy Revenue Market Share by Players (2021-2026) Table 23. Global Viral Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Viral Gene Therapy Key Players Headquarters & Area Served Table 25. Global Viral Gene Therapy Players, Product Type & Application Table 26. Global Viral Gene Therapy Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Viral Gene Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Viral Gene Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Viral Gene Therapy Revenue Market Share by Type (2021-2026) Table 33. Global Viral Gene Therapy Revenue Market Share by Type (2027-2032) Table 34. Global Viral Gene Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Viral Gene Therapy Revenue Market Share by Application (2021-2026) Table 38. Global Viral Gene Therapy Revenue Market Share by Application (2027-2032) Table 39. AnGes Company Information Table 40. AnGes Business Overview Table 41. AnGes Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. AnGes Viral Gene Therapy Product Portfolio Table 43. AnGes Recent Development Table 44. Catalent Company Information Table 45. Catalent Business Overview Table 46. Catalent Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Catalent Viral Gene Therapy Product Portfolio Table 48. Catalent Recent Development Table 49. Ionis Pharmaceuticals Company Information Table 50. Ionis Pharmaceuticals Business Overview Table 51. Ionis Pharmaceuticals Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio Table 53. Ionis Pharmaceuticals Recent Development Table 54. Orchard Therapeutics Company Information Table 55. Orchard Therapeutics Business Overview Table 56. Orchard Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Orchard Therapeutics Viral Gene Therapy Product Portfolio Table 58. Orchard Therapeutics Recent Development Table 59. Sarepta Therapeutics Company Information Table 60. Sarepta Therapeutics Business Overview Table 61. Sarepta Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sarepta Therapeutics Viral Gene Therapy Product Portfolio Table 63. Sarepta Therapeutics Recent Development Table 64. SIBIONO Company Information Table 65. SIBIONO Business Overview Table 66. SIBIONO Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. SIBIONO Viral Gene Therapy Product Portfolio Table 68. SIBIONO Recent Development Table 69. Spark Therapeutics Company Information Table 70. Spark Therapeutics Business Overview Table 71. Spark Therapeutics Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Spark Therapeutics Viral Gene Therapy Product Portfolio Table 73. Spark Therapeutics Recent Development Table 74. Amgen Company Information Table 75. Amgen Business Overview Table 76. Amgen Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Amgen Viral Gene Therapy Product Portfolio Table 78. Amgen Recent Development Table 79. Biogen Company Information Table 80. Biogen Business Overview Table 81. Biogen Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Biogen Viral Gene Therapy Product Portfolio Table 83. Biogen Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Viral Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Gilead Sciences Viral Gene Therapy Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Lonza Company Information Table 90. Lonza Business Overview Table 91. Lonza Viral Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Lonza Viral Gene Therapy Product Portfolio Table 93. Lonza Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis Viral Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Novartis Viral Gene Therapy Product Portfolio Table 98. Novartis Recent Development Table 99. Shanghai Sunway Biotech Company Information Table 100. Shanghai Sunway Biotech Business Overview Table 101. Shanghai Sunway Biotech Viral Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio Table 103. Shanghai Sunway Biotech Recent Development Table 104. North America Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 105. North America Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 106. North America Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 107. North America Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 108. North America Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America Viral Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 110. North America Viral Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe Viral Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe Viral Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 118. China Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 119. China Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 120. China Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 121. China Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Viral Gene Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia Viral Gene Therapy Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia Viral Gene Therapy Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA Viral Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA Viral Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA Viral Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA Viral Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA Viral Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA Viral Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Viral Gene Therapy Image Figure 2. Global Viral Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Integrating Viral Vectors Image Figure 5. Non-Integrating Viral Vectors Image Figure 6. Global Viral Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Viral Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Ophthalmologic Diseases Image Figure 9. Hematologic Diseases Image Figure 10. Cardiovascular Diseases Image Figure 11. Muscular Diseases Image Figure 12. Metabolic Diseases Image Figure 13. Infectious Diseases Image Figure 14. Others Image Figure 15. Global Viral Gene Therapy Market Size (US$ Million) & (2021-2032) Figure 16. Global Viral Gene Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Viral Gene Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Viral Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Viral Gene Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Viral Gene Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Viral Gene Therapy Revenue Market Share by Type (2021-2032) Figure 23. Global Viral Gene Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Viral Gene Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Viral Gene Therapy Revenue Market Share by Application (2021-2032) Figure 26. North America Viral Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Viral Gene Therapy Revenue Share by Type (2021-2032) Figure 28. North America Viral Gene Therapy Revenue Share by Application (2021-2032) Figure 29. North America Viral Gene Therapy Revenue Share by Country (2021-2032) Figure 30. United States Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Viral Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Viral Gene Therapy Revenue Share by Type (2021-2032) Figure 35. Europe Viral Gene Therapy Revenue Share by Application (2021-2032) Figure 36. Europe Viral Gene Therapy Revenue Share by Country (2021-2032) Figure 37. Germany Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Viral Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Viral Gene Therapy Revenue Share by Type (2021-2032) Figure 47. China Viral Gene Therapy Revenue Share by Application (2021-2032) Figure 48. Asia Viral Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Viral Gene Therapy Revenue Share by Type (2021-2032) Figure 50. Asia Viral Gene Therapy Revenue Share by Application (2021-2032) Figure 51. Asia Viral Gene Therapy Revenue Share by Region (2021-2032) Figure 52. Japan Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Viral Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Viral Gene Therapy Revenue Share by Type (2021-2032) Figure 60. SAMEA Viral Gene Therapy Revenue Share by Application (2021-2032) Figure 61. SAMEA Viral Gene Therapy Revenue Share by Country (2021-2032) Figure 62. Brazil Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Viral Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Integrating Viral Vectors
  • Non-Integrating Viral Vectors
Applications
  • Ophthalmologic Diseases
  • Hematologic Diseases
  • Cardiovascular Diseases
  • Muscular Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Others
Companies covered
  • AnGes
  • Catalent
  • Ionis Pharmaceuticals
  • Orchard Therapeutics
  • Sarepta Therapeutics
  • SIBIONO
  • Spark Therapeutics
  • Amgen
  • Biogen
  • Gilead Sciences
  • Lonza
  • Novartis
  • Shanghai Sunway Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Viral Gene Therapy Market by Type
  3. 1.2.1 Global Viral Gene Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Integrating Viral Vectors
  5. 1.2.3 Non-Integrating Viral Vectors
  6. 1.3 Viral Gene Therapy Market by Application
  7. 1.3.1 Global Viral Gene Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Ophthalmologic Diseases
  9. 1.3.3 Hematologic Diseases
  10. 1.3.4 Cardiovascular Diseases
  11. 1.3.5 Muscular Diseases
  12. 1.3.6 Metabolic Diseases
  13. 1.3.7 Infectious Diseases
  14. 1.3.8 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Viral Gene Therapy Market Dynamics
  1. 2.1 Viral Gene Therapy Industry Trends
  2. 2.2 Viral Gene Therapy Industry Drivers
  3. 2.3 Viral Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Viral Gene Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Viral Gene Therapy Market Perspective (2021-2032)
  2. 3.2 Global Viral Gene Therapy Growth Trends by Region
  3. 3.2.1 Global Viral Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Viral Gene Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Viral Gene Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Viral Gene Therapy Revenue by Players
  2. 4.1.1 Global Viral Gene Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Viral Gene Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Viral Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Viral Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Viral Gene Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Viral Gene Therapy Players, Product Type & Application
  8. 4.5 Global Viral Gene Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Viral Gene Therapy Market CR5 and HHI
  11. 4.6.3 2025 Viral Gene Therapy Tier 1, Tier 2, and Tier 3
5 Viral Gene Therapy Market Size by Type
  1. 5.1 Global Viral Gene Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Viral Gene Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Viral Gene Therapy Revenue Market Share by Type (2021-2032)
6 Viral Gene Therapy Market Size by Application
  1. 6.1 Global Viral Gene Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Viral Gene Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Viral Gene Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AnGes
  2. 7.1.1 AnGes Company Information
  3. 7.1.2 AnGes Business Overview
  4. 7.1.3 AnGes Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AnGes Viral Gene Therapy Product Portfolio
  6. 7.1.5 AnGes Recent Developments
  7. 7.2 Catalent
  8. 7.2.1 Catalent Company Information
  9. 7.2.2 Catalent Business Overview
  10. 7.2.3 Catalent Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Catalent Viral Gene Therapy Product Portfolio
  12. 7.2.5 Catalent Recent Developments
  13. 7.3 Ionis Pharmaceuticals
  14. 7.3.1 Ionis Pharmaceuticals Company Information
  15. 7.3.2 Ionis Pharmaceuticals Business Overview
  16. 7.3.3 Ionis Pharmaceuticals Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
  18. 7.3.5 Ionis Pharmaceuticals Recent Developments
  19. 7.4 Orchard Therapeutics
  20. 7.4.1 Orchard Therapeutics Company Information
  21. 7.4.2 Orchard Therapeutics Business Overview
  22. 7.4.3 Orchard Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Orchard Therapeutics Viral Gene Therapy Product Portfolio
  24. 7.4.5 Orchard Therapeutics Recent Developments
  25. 7.5 Sarepta Therapeutics
  26. 7.5.1 Sarepta Therapeutics Company Information
  27. 7.5.2 Sarepta Therapeutics Business Overview
  28. 7.5.3 Sarepta Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sarepta Therapeutics Viral Gene Therapy Product Portfolio
  30. 7.5.5 Sarepta Therapeutics Recent Developments
  31. 7.6 SIBIONO
  32. 7.6.1 SIBIONO Company Information
  33. 7.6.2 SIBIONO Business Overview
  34. 7.6.3 SIBIONO Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 SIBIONO Viral Gene Therapy Product Portfolio
  36. 7.6.5 SIBIONO Recent Developments
  37. 7.7 Spark Therapeutics
  38. 7.7.1 Spark Therapeutics Company Information
  39. 7.7.2 Spark Therapeutics Business Overview
  40. 7.7.3 Spark Therapeutics Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Spark Therapeutics Viral Gene Therapy Product Portfolio
  42. 7.7.5 Spark Therapeutics Recent Developments
  43. 7.8 Amgen
  44. 7.8.1 Amgen Company Information
  45. 7.8.2 Amgen Business Overview
  46. 7.8.3 Amgen Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amgen Viral Gene Therapy Product Portfolio
  48. 7.8.5 Amgen Recent Developments
  49. 7.9 Biogen
  50. 7.9.1 Biogen Company Information
  51. 7.9.2 Biogen Business Overview
  52. 7.9.3 Biogen Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Biogen Viral Gene Therapy Product Portfolio
  54. 7.9.5 Biogen Recent Developments
  55. 7.10 Gilead Sciences
  56. 7.10.1 Gilead Sciences Company Information
  57. 7.10.2 Gilead Sciences Business Overview
  58. 7.10.3 Gilead Sciences Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Gilead Sciences Viral Gene Therapy Product Portfolio
  60. 7.10.5 Gilead Sciences Recent Developments
  61. 7.11 Lonza
  62. 7.11.1 Lonza Company Information
  63. 7.11.2 Lonza Business Overview
  64. 7.11.3 Lonza Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lonza Viral Gene Therapy Product Portfolio
  66. 7.11.5 Lonza Recent Developments
  67. 7.12 Novartis
  68. 7.12.1 Novartis Company Information
  69. 7.12.2 Novartis Business Overview
  70. 7.12.3 Novartis Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Novartis Viral Gene Therapy Product Portfolio
  72. 7.12.5 Novartis Recent Developments
  73. 7.13 Shanghai Sunway Biotech
  74. 7.13.1 Shanghai Sunway Biotech Company Information
  75. 7.13.2 Shanghai Sunway Biotech Business Overview
  76. 7.13.3 Shanghai Sunway Biotech Viral Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
  78. 7.13.5 Shanghai Sunway Biotech Recent Developments
8 North America
  1. 8.1 North America Viral Gene Therapy Revenue (2021-2032)
  2. 8.2 North America Viral Gene Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Viral Gene Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Viral Gene Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Viral Gene Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Viral Gene Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Viral Gene Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Viral Gene Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Viral Gene Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Viral Gene Therapy Revenue by Country
  11. 8.6.1 North America Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Viral Gene Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Viral Gene Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Viral Gene Therapy Revenue (2021-2032)
  2. 9.2 Europe Viral Gene Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Viral Gene Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Viral Gene Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Viral Gene Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Viral Gene Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Viral Gene Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Viral Gene Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Viral Gene Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Viral Gene Therapy Revenue by Country
  11. 9.6.1 Europe Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Viral Gene Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Viral Gene Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Viral Gene Therapy Revenue (2021-2032)
  2. 10.2 China Viral Gene Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Viral Gene Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Viral Gene Therapy Revenue by Type (2027-2032)
  5. 10.3 China Viral Gene Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Viral Gene Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Viral Gene Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Viral Gene Therapy Revenue by Application (2027-2032)
  9. 10.5 China Viral Gene Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Viral Gene Therapy Revenue (2021-2032)
  2. 11.2 Asia Viral Gene Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Viral Gene Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Viral Gene Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Viral Gene Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Viral Gene Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Viral Gene Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Viral Gene Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Viral Gene Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Viral Gene Therapy Revenue by Country
  11. 11.6.1 Asia Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Viral Gene Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Viral Gene Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Viral Gene Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Viral Gene Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Viral Gene Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Viral Gene Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Viral Gene Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Viral Gene Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Viral Gene Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Viral Gene Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Viral Gene Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Viral Gene Therapy Revenue by Country
  11. 12.6.1 SAMEA Viral Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Viral Gene Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Viral Gene Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst